<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39098944</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-2592</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of clinical immunology</Title><ISOAbbreviation>J Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>A Novel Case of IFNAR1 Deficiency Identified a Common Canonical Splice Site Variant in DOCK8 in Western Polynesia: The Importance of Validating Variants of Unknown Significance in Under-Represented Ancestries.</ArticleTitle><Pagination><StartPage>170</StartPage><MedlinePgn>170</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">170</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10875-024-01774-x</ELocationID><Abstract><AbstractText>Advanced genomic technologies such as whole exome or whole genome sequencing have improved diagnoses and disease outcomes for individuals with genetic diseases. Yet, variants of unknown significance (VUS) require rigorous validation to establish disease causality or modification, or to exclude them from further analysis. Here, we describe a young individual of Polynesian ancestry who in the first 13 mo of life presented with SARS-CoV-2 pneumonia, severe enterovirus meningitis and adenovirus gastroenteritis, and severe adverse reaction to MMR vaccination. Genomic analysis identified a previously reported pathogenic homozygous variant in IFNAR1 (c.1156G &gt; T, p.Glu386* LOF), which is common in Western Polynesia. Moreover, a new and putatively deleterious canonical splice site variant in DOCK8 was also found in homozygosity (c.3234 + 2T &gt; C). This DOCK8 variant is common in Polynesians and other under-represented ancestries in large genomic databases. Despite in silico bioinformatic predictions, extensive in vitro and ex vivo analysis revealed the DOCK8 variant likely be neutral. Thus, our study reports a novel case of IFNAR1 deficiency, but also highlights the importance of functional validation of VUS, including those predicted to be deleterious, and the pressing need to expand our knowledge of the genomic architecture and landscape of under-represented populations and ancestries.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huynh</LastName><ForeName>Aimee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Queensland Paediatric Immunology and Allergy Service, Children's Health Queensland, Brisbane, QLD, 4101, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Paul E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School Medicine, Western Sydney University, Penrith, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Queensland Paediatric Immunology and Allergy Service, Children's Health Queensland, Brisbane, QLD, 4101, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackie</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerin</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Geetha</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathmanandavel</LastName><ForeName>Karrnan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mina</LastName><ForeName>Erika Della</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hollway</LastName><ForeName>Georgina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hobbs</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enthoven</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Young</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McManus</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Royal Brisbane and Women's Hospital, Herston, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wainwright</LastName><ForeName>Luke H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Royal Brisbane and Women's Hospital, Herston, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higgins</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Genetic Health Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noon</LastName><ForeName>Fallon</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Genetic Health Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Allergy and Immunology, The Children's Hospital at Westmead, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Paris, Imagine Institute, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Necker Hospital for Sick Children, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casanova</LastName><ForeName>Jean-Laurent</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Paris, Imagine Institute, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Necker Hospital for Sick Children, AP-HP, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Kuang-Chih</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Starship Child Health, Auckland, New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pinzon-Charry</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Queensland Paediatric Immunology and Allergy Service, Children's Health Queensland, Brisbane, QLD, 4101, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Griffith University and University of Queensland, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ma</LastName><ForeName>Cindy S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tangye</LastName><ForeName>Stuart G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Clinical Immunogenomics Research Consortium, Australasia, Australia. s.tangye@garvan.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia. s.tangye@garvan.org.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia. s.tangye@garvan.org.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Immunol</MedlineTA><NlmUniqueID>8102137</NlmUniqueID><ISSNLinking>0271-9142</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020662">Guanine Nucleotide Exchange Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>156986-95-7</RegistryNumber><NameOfSubstance UI="D053633">Receptor, Interferon alpha-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C516591">DOCK8 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C507964">IFNAR1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022821">RNA Splice Sites</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Clin Immunol. 2024 Sep 19;45(1):11. doi: 10.1007/s10875-024-01801-x</RefSource><PMID Version="1">39297999</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020662" MajorTopicYN="Y">Guanine Nucleotide Exchange Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053633" MajorTopicYN="Y">Receptor, Interferon alpha-beta</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022821" MajorTopicYN="N">RNA Splice Sites</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>5</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>5</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>4</Day><Hour>23</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39098944</ArticleId><ArticleId IdType="pmc">PMC11298505</ArticleId><ArticleId IdType="doi">10.1007/s10875-024-01774-x</ArticleId><ArticleId IdType="pii">10.1007/s10875-024-01774-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hernandez N, Bucciol G, Moens L, Le Pen J, Shahrooei M, Goudouris E, et al. Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J Exp Med. 2019;216(9):2057–70. 10.1084/jem.20182295</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20182295</ArticleId><ArticleId IdType="pmc">PMC6719432</ArticleId><ArticleId IdType="pubmed">31270247</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothe F, Hatton CF, Truong L, Klimova Z, Kanderova V, Fejtkova M, et al. A novel case of homozygous Interferon Alpha/Beta receptor alpha chain (IFNAR1) Deficiency with Hemophagocytic Lymphohistiocytosis. Clin Infect Dis. 2022;74(1):136–9. 10.1093/cid/ciaa1790</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1790</ArticleId><ArticleId IdType="pmc">PMC8752251</ArticleId><ArticleId IdType="pubmed">33252644</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyts I, Casanova JL. Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway. Eur J Immunol. 2021;51(5):1039–61. 10.1002/eji.202048793</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202048793</ArticleId><ArticleId IdType="pmc">PMC8900014</ArticleId><ArticleId IdType="pubmed">33729549</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Matuozzo D, Le Pen J, Lee D, Moens L, Asano T et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J Exp Med. 2022;219(8).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9206114</ArticleId><ArticleId IdType="pubmed">35708626</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciol G, Human Genetic COVID, Effort, Meyts I. Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children. J Allergy Clin Immunol. 2023;151(4):832–40. 10.1016/j.jaci.2023.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2023.02.003</ArticleId><ArticleId IdType="pmc">PMC9951110</ArticleId><ArticleId IdType="pubmed">36841740</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang SY, Jouanguy E, Zhang Q, Abel L, Puel A, Casanova JL. Human inborn errors of immunity to infection affecting cells other than leukocytes: from the immune system to the whole organism. Curr Opin Immunol. 2019;59:88–100. 10.1016/j.coi.2019.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2019.03.008</ArticleId><ArticleId IdType="pmc">PMC6774828</ArticleId><ArticleId IdType="pubmed">31121434</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye SG. Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. J Allergy Clin Immunol. 2023;151(4):818–31. 10.1016/j.jaci.2022.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2022.11.010</ArticleId><ArticleId IdType="pmc">PMC9746792</ArticleId><ArticleId IdType="pubmed">36522221</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan CJ, Mohamad SM, Young DF, Skelton AJ, Leahy TR, Munday DC, et al. Human IFNAR2 deficiency: lessons for antiviral immunity. Sci Transl Med. 2015;7(307):307ra154. 10.1126/scitranslmed.aac4227</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac4227</ArticleId><ArticleId IdType="pmc">PMC4926955</ArticleId><ArticleId IdType="pubmed">26424569</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan CJA, Skouboe MK, Howarth S, Hollensen AK, Chen R, Borresen ML et al. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. J Exp Med. 2022;219(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9026249</ArticleId><ArticleId IdType="pubmed">35442417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Michailidis E, Hoffmann HH, Chbihi M, Le Voyer T, Rosain J et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med. 2021;218(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7871457</ArticleId><ArticleId IdType="pubmed">33544838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Gervais A, Taniguchi M, Saare L, Sarekannu K, Le Voyer T et al. Higher COVID-19 pneumonia risk associated with anti-IFN-alpha than with anti-IFN-omega auto-abs in children. J Exp Med. 2024;221(2).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10771097</ArticleId><ArticleId IdType="pubmed">38175961</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyts I. Null IFNAR1 and IFNAR2 alleles are surprisingly common in the Pacific and Arctic. J Exp Med. 2022;219(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9070088</ArticleId><ArticleId IdType="pubmed">35486090</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Hsiao KC, Zhang Q, Choin J, Best E, Chen J et al. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. J Exp Med. 2022;219(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9026234</ArticleId><ArticleId IdType="pubmed">35442418</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Francioli LC, Goodrich JK, Collins RL, Kanai M, Wang Q, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature. 2024;625(7993):92–100. 10.1038/s41586-023-06045-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06045-0</ArticleId><ArticleId IdType="pubmed">38057664</ArticleId></ArticleIdList></Reference><Reference><Citation>Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med. 2010;207(1):155–71. 10.1084/jem.20091706</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20091706</ArticleId><ArticleId IdType="pmc">PMC2812540</ArticleId><ArticleId IdType="pubmed">20048285</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay BA, Avery DT, Smart JM, Cole T, Choo S, Chan D et al. Hematopoietic stem cell transplant effectively rescues lymphocyte differentiation and function in DOCK8-deficient patients. JCI Insight. 2019;5(11).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6629099</ArticleId><ArticleId IdType="pubmed">31021819</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay BA, Fusaro M, Gray PE, Statham AL, Burnett L, Bezrodnik L et al. Somatic reversion of pathogenic DOCK8 variants alters lymphocyte differentiation and function to effectively cure DOCK8 deficiency. J Clin Invest. 2021;131(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7843233</ArticleId><ArticleId IdType="pubmed">33290277</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye SG, Pillay B, Randall KL, Avery DT, Phan TG, Gray P, et al. Dedicator of cytokinesis 8-deficient CD4(+) T cells are biased to a T(H)2 effector fate at the expense of T(H)1 and T(H)17 cells. J Allergy Clin Immunol. 2017;139(3):933–49. 10.1016/j.jaci.2016.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.07.016</ArticleId><ArticleId IdType="pmc">PMC10500883</ArticleId><ArticleId IdType="pubmed">27554822</ArticleId></ArticleIdList></Reference><Reference><Citation>Tangye SG, Gray PE, Pillay BA, Yap JY, Figgett WA, Reeves J, et al. Hyper-IgE syndrome due to an Elusive Novel Intronic homozygous variant in DOCK8. J Clin Immunol. 2022;42(1):119–29. 10.1007/s10875-021-01152-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01152-x</ArticleId><ArticleId IdType="pmc">PMC10461790</ArticleId><ArticleId IdType="pubmed">34657245</ArticleId></ArticleIdList></Reference><Reference><Citation>Randall KL, Chan SS, Ma CS, Fung I, Mei Y, Yabas M, et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med. 2011;208(11):2305–20. 10.1084/jem.20110345</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20110345</ArticleId><ArticleId IdType="pmc">PMC3201196</ArticleId><ArticleId IdType="pubmed">22006977</ArticleId></ArticleIdList></Reference><Reference><Citation>Summers KM. Genetic models of fibrillinopathies. Genetics. 2024;226(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11021029</ArticleId><ArticleId IdType="pubmed">37972149</ArticleId></ArticleIdList></Reference><Reference><Citation>Itan Y, Shang L, Boisson B, Ciancanelli MJ, Markle JG, Martinez-Barricarte R, et al. The mutation significance cutoff: gene-level thresholds for variant predictions. Nat Methods. 2016;13(2):109–10. 10.1038/nmeth.3739</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3739</ArticleId><ArticleId IdType="pmc">PMC4980758</ArticleId><ArticleId IdType="pubmed">26820543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–5. 10.1038/ng.2892</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2892</ArticleId><ArticleId IdType="pmc">PMC3992975</ArticleId><ArticleId IdType="pubmed">24487276</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinese M, Lacaze P, Rath EM, Stone A, Brion MJ, Ameur A, et al. The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly. Nat Commun. 2020;11(1):435. 10.1038/s41467-019-14079-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14079-0</ArticleId><ArticleId IdType="pmc">PMC6978518</ArticleId><ArticleId IdType="pubmed">31974348</ArticleId></ArticleIdList></Reference><Reference><Citation>Choin J, Mendoza-Revilla J, Arauna LR, Cuadros-Espinoza S, Cassar O, Larena M, et al. Genomic insights into population history and biological adaptation in Oceania. Nature. 2021;592(7855):583–9. 10.1038/s41586-021-03236-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03236-5</ArticleId><ArticleId IdType="pubmed">33854233</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Herz W, Ragupathy R, Massaad MJ, Al-Attiyah R, Nanda A, Engelhardt KR, et al. Clinical, immunologic and genetic profiles of DOCK8-deficient patients in Kuwait. Clin Immunol. 2012;143(3):266–72. 10.1016/j.clim.2012.03.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2012.03.002</ArticleId><ArticleId IdType="pmc">PMC3893030</ArticleId><ArticleId IdType="pubmed">22534316</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt KR, Gertz ME, Keles S, Schaffer AA, Sigmund EC, Glocker C, et al. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2015;136(2):402–12. 10.1016/j.jaci.2014.12.1945</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.12.1945</ArticleId><ArticleId IdType="pmc">PMC4530066</ArticleId><ArticleId IdType="pubmed">25724123</ArticleId></ArticleIdList></Reference><Reference><Citation>Su HC, Jing H, Angelus P, Freeman AF. Insights into immunity from clinical and basic science studies of DOCK8 immunodeficiency syndrome. Immunol Rev. 2019;287(1):9–19. 10.1111/imr.12723</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12723</ArticleId><ArticleId IdType="pmc">PMC6350515</ArticleId><ArticleId IdType="pubmed">30565250</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options - a review of 136 patients. J Clin Immunol. 2015;35(2):189–98. 10.1007/s10875-014-0126-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-014-0126-0</ArticleId><ArticleId IdType="pubmed">25627830</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Davis JC, Lamborn IT, Freeman AF, Jing H, Favreau AJ, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med. 2009;361(21):2046–55. 10.1056/NEJMoa0905506</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0905506</ArticleId><ArticleId IdType="pmc">PMC2965730</ArticleId><ArticleId IdType="pubmed">19776401</ArticleId></ArticleIdList></Reference><Reference><Citation>Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol. 2018;141(4):1450–8. 10.1016/j.jaci.2017.06.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2017.06.049</ArticleId><ArticleId IdType="pubmed">28916186</ArticleId></ArticleIdList></Reference><Reference><Citation>Arts P, Simons A, AlZahrani MS, Yilmaz E, AlIdrissi E, van Aerde KJ, et al. Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies. Genome Med. 2019;11(1):38. 10.1186/s13073-019-0649-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-019-0649-3</ArticleId><ArticleId IdType="pmc">PMC6572765</ArticleId><ArticleId IdType="pubmed">31203817</ArticleId></ArticleIdList></Reference><Reference><Citation>Yska HAF, Elsink K, Kuijpers TW, Frederix GWJ, van Gijn ME, van Montfrans JM. Diagnostic yield of Next Generation sequencing in genetically undiagnosed patients with primary immunodeficiencies: a systematic review. J Clin Immunol. 2019;39(6):577–91. 10.1007/s10875-019-00656-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-019-00656-x</ArticleId><ArticleId IdType="pmc">PMC6697711</ArticleId><ArticleId IdType="pubmed">31250335</ArticleId></ArticleIdList></Reference><Reference><Citation>Stray-Pedersen A, Sorte HS, Samarakoon P, Gambin T, Chinn IK, Coban Akdemir ZH, et al. Primary immunodeficiency diseases: genomic approaches delineate heterogeneous mendelian disorders. J Allergy Clin Immunol. 2017;139(1):232–45. 10.1016/j.jaci.2016.05.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2016.05.042</ArticleId><ArticleId IdType="pmc">PMC5222743</ArticleId><ArticleId IdType="pubmed">27577878</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorsteveld EE, Hoischen A, van der Made CI. Next-generation sequencing in the field of primary immunodeficiencies: current yield, challenges, and future perspectives. Clin Rev Allergy Immunol. 2021;61(2):212–25. 10.1007/s12016-021-08838-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08838-5</ArticleId><ArticleId IdType="pmc">PMC7934351</ArticleId><ArticleId IdType="pubmed">33666867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan KE. The scary world of variants of uncertain significance (VUS): a hitchhiker’s guide to interpretation. J Allergy Clin Immunol. 2021;147(2):492–4. 10.1016/j.jaci.2020.06.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.06.011</ArticleId><ArticleId IdType="pubmed">32598897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyos-Bachiloglu R, Chou J, Sodroski CN, Beano A, Bainter W, Angelova M, et al. A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations. J Clin Invest. 2017;127(12):4415–20. 10.1172/JCI93486</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI93486</ArticleId><ArticleId IdType="pmc">PMC5707159</ArticleId><ArticleId IdType="pubmed">29106381</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MWY, Burnett L, Dai P, Avery DT, Noori T, Voskoboinik I, et al. Filaggrin-Associated atopic skin, Eye, Airways, and Gut Disease, modifying the presentation of X-Linked reticular pigmentary disorder (XLPDR). J Clin Immunol. 2024;44(1):38. 10.1007/s10875-023-01637-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-023-01637-x</ArticleId><ArticleId IdType="pubmed">38165470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q. Human genetics of life-threatening influenza pneumonitis. Hum Genet. 2020;139(6–7):941–8. 10.1007/s00439-019-02108-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-019-02108-3</ArticleId><ArticleId IdType="pmc">PMC7094886</ArticleId><ArticleId IdType="pubmed">32025908</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciol G, Moens L, Ogishi M, Rinchai D, Matuozzo D, Momenilandi M et al. Human inherited complete STAT2 deficiency underlies inflammatory viral diseases. J Clin Invest. 2023;133(12).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10266780</ArticleId><ArticleId IdType="pubmed">36976641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JH, Tang XY, Boulling A, Zou WB, Masson E, Fichou Y, et al. First estimate of the scale of canonical 5’ splice site GT &gt; GC variants capable of generating wild-type transcripts. Hum Mutat. 2019;40(10):1856–73. 10.1002/humu.23821</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23821</ArticleId><ArticleId IdType="pubmed">31131953</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh RY, AlMail A, Cheerie D, Guirguis G, Hou H, Yuki KE, et al. A systematic assessment of the impact of rare canonical splice site variants on splicing using functional and in silico methods. HGG Adv. 2024;5(3):100299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11144818</ArticleId><ArticleId IdType="pubmed">38659227</ArticleId></ArticleIdList></Reference><Reference><Citation>Woon ST, Tjandra F, Mackay J, Lumley T, Grainger P, Wood A, et al. Detection of interferon alpha and beta receptor subunit 1 (IFNAR1) loss-of-function Glu386 * variant by tri-allelic genotyping. Pathology. 2024;56(1):92–7. 10.1016/j.pathol.2023.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pathol.2023.09.006</ArticleId><ArticleId IdType="pubmed">37973454</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>